Medpage Today reports that the long-awaited updates to the American College of Rheumatology's (ACR) guideline on systemic lupus erythematosus (SLE) management make clear that hydroxychloroquine (HCQ) should be the centerpiece of treatment for most patients, with other medication classes added as needed to reach low disease activity (LDA) or remission.

Written by Lisa R. Sammaritano, MD, rheumatologist at HSS, and a committee of nearly 50 other experts, the new guideline also stipulates that corticosteroids are OK for gaining symptom control in newly diagnosed patients and when flares erupt, but the duration should be kept as short as possible.

Read the full article at medpagetoday.com.